Proton Beam Therapy of Parapapillary Choroidal Melanoma

Cataract Avoidance With Proton Therapy in Ocular Melanomas

“…Radiationinduced cataracts, although curable, are involved in vision deterioration in 30% to 80% of uveal melanoma patients after PT, brachytherapy, or stereotactic irradiation. [11][12][13][14] Cataracts are usually considered a minor complication of cancer treatments because VICs are easily manageable with extracapsular lens extraction and intraocular lens implant placement. However, Gragoudas et al 7 reported significant postoperative complications in 16% of patients following PT for ocular melanomas.…”

“…28,29 The incidence of cataracts appears to be smaller than in other radiotherapy series. 5,6,[11][12][13]24,30 This could be partly explained by the relatively short median follow up or by 6month intervals between exams, which may underestimate this incidence. However, high-dose rate and high radiation dose are associated with short latency rather than with more fractionated dose regimens.…”

Trabeculectomy in patients with uveal melanoma after proton beam therapy

“…Today, high local tumor control rates can be achieved by radiation based methods, e.g. brachytherapy and proton beam therapy [2]. Enucleation due to local recurrence of the tumor remains exceptional.…”

Novel mouse model for primary uveal melanoma: a pilot study

“…The reported tumour control rates are quite good. However, vision is frequently significantly impaired, either if the tumours are located posteriorly near the fovea and optic disc or by treatment‐related complications, such as radiation retinopathy and opticopathy . Despite these conventional therapeutic modalities, it would be quite interesting to study novel treatment strategies, such as targeted therapies aimed at influencing tumour cells on the molecular level concerning tumour regression, as well as ocular side effects.…”

“…However, vision is frequently significantly impaired, either if the tumours are located posteriorly near the fovea and optic disc or by treatment-related complications, such as radiation retinopathy and opticopathy. 7,8 Despite these conventional therapeutic modalities, it would be quite interesting to study novel treatment strategies, such as targeted therapies aimed at influencing tumour cells on the molecular level concerning tumour regression, as well as ocular side effects. To investigate these new therapeutic agents, it is first necessary to analyse tumour cells at the molecular level to determine the changes in protein expression and genetics that occur in these cells.…”